Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (13)
Poster categories
  • Thematic Poster Session (22)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • TPS33 (12)
  • TPS34 (10)
  • x TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • x TPS66 (7)
  • TPS67 (10)
  • TPS68 (5)
  • TPS69 (11)
  • x TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • TPS91 (3)
22 results
Thumbnail

D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure

Thumbnail

D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings

Thumbnail

D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents

Thumbnail

D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study

Thumbnail

D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels

Thumbnail

D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update

Thumbnail

D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment

Thumbnail

D3.126 - Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFiRM Score: A Real-Life Cohort Analysis

Thumbnail

D3.129 - Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma

Thumbnail

D3.132 - The impact of biological therapy on the quality of life of patients with severe asthma

Thumbnail

D3.135 - Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience

Thumbnail

D3.137 - The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma

Thumbnail

D3.138 - Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study

Thumbnail

D3.139 - Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study

Thumbnail

D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study

Thumbnail

D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials

Thumbnail

D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy

Thumbnail

D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure

Thumbnail

D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents

Thumbnail

D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM